Fischer Medical Ventures Q2 profit driven by other income

Fischer Medical Ventures Limited reported standalone profit after tax of Rs 20.58 crore for the quarter ended September 30, 2026, as other income of Rs 30.38 crore outweighed revenue from operations of Rs 27.62 lakh. The parent company’s profit followed non-operating income while its revenue from operations fell from Rs 7.43 crore a year earlier.

Why did Fischer Medical Ventures report a Rs 20.58 crore Q2 profit?

Fischer Medical Ventures reported Rs 20.58 crore of standalone profit after tax because Rs 30.38 crore of other income offset total expenses of Rs 4.58 crore in the September 2026 quarter. Total income was Rs 30.65 crore, profit before tax was Rs 26.08 crore, and current and deferred tax charges together were Rs 5.50 crore.

Revenue from operations less total expenses was negative Rs 4.30 crore before other income in the September 2026 quarter. Other income was about 110 times the Rs 27.62 lakh operating revenue and represented almost all of total income. The statement reported no exceptional item, meaning the income was presented within other income rather than separately as exceptional income.

The outcome differed from the quarter ended September 30, 2025, when Fischer Medical Ventures reported Rs 7.43 crore of operating revenue, Rs 1.43 crore of other income and Rs 7.48 crore of expenses. Profit after tax was Rs 83.77 lakh in that earlier quarter. In September 2026, other income rose by Rs 28.94 crore year on year while revenue from operations declined by Rs 7.15 crore.

How much did Fischer Medical Ventures' operating revenue decline in Q2?

Fischer Medical Ventures’ standalone revenue from operations fell about 96% year on year to Rs 27.62 lakh in the quarter ended September 30, 2026, from Rs 7.43 crore a year earlier. Revenue also declined from Rs 72.17 lakh in the quarter ended June 30, 2026, indicating a sequential reduction as well as a year-on-year fall.

For the half year ended September 30, 2026, revenue from operations was Rs 99.79 lakh, against Rs 11.97 crore in the corresponding prior-year half year. Other income, however, increased to Rs 31.27 crore from Rs 2.24 crore. This lifted half-year profit after tax to Rs 17.07 crore from Rs 22.83 lakh despite the fall in operating revenue.

Costs did not decline uniformly with revenue during the September 2026 quarter. Purchases of traded goods fell to Rs 3.49 crore from Rs 4.63 crore a year earlier, while changes in inventories produced a Rs 2.88 crore reduction in expense. Employee benefits rose to Rs 65.10 lakh from Rs 45.46 lakh, finance cost rose to Rs 1.29 crore from Rs 1.12 crore, and depreciation and amortisation rose to Rs 77.99 lakh from Rs 8.16 lakh.

What does the half-year cash flow show about Fischer Medical Ventures' profit?

Fischer Medical Ventures used Rs 33.45 crore in operating activities in the half year ended September 30, 2026, despite reporting Rs 22.85 crore of standalone profit before tax. The cash-flow statement deducts Rs 27.05 crore of dividend income in reconciling profit before tax to operating profit before working-capital changes, which was negative Rs 1.37 crore.

Dividend income of Rs 27.05 crore equalled about 86% of the Rs 31.27 crore of other income reported for the half year. The filing does not provide a quarterly breakdown of other income, so it does not establish the amount of September-quarter other income that was dividend income. It does establish that dividend income was the largest disclosed adjustment in the half-year operating cash-flow reconciliation.

Working-capital movements increased the cash outflow. Other current assets increased by Rs 28.98 crore, inventories increased by Rs 2.95 crore, and net working-capital changes were negative Rs 30.41 crore. Cash generated from operations was therefore negative Rs 31.78 crore, followed by Rs 1.67 crore of income taxes paid; operating cash used was Rs 9.39 lakh in the corresponding 2025 half year.

The investing section records Rs 1.65 crore of dividends received from a subsidiary during the latest half year, compared with the Rs 27.05 crore dividend-income adjustment in the operating reconciliation. The statement does not explain the difference between income recognised and dividends received in cash, including any timing or balance-sheet treatment. It separately records Rs 78.49 lakh of interest income in investing cash flows.

How did Fischer Medical Ventures' funding and balance sheet change?

Fischer Medical Ventures ended September 30, 2026 with cash and cash equivalents of Rs 26.5178 crore, up from Rs 1.1385 crore at March 31, 2026. Net financing cash inflow was Rs 82.9275 crore, including Rs 77.5184 crore from equity shares issued upon conversion of warrants and Rs 11.4804 crore of net long-term borrowing proceeds.

The board approved warrant-conversion allotments between August 11 and August 17, 2026 at an issue price of Rs 23.40 per equity share, including a Rs 22.40 premium. The balance exercise price collected was Rs 17.55 per warrant. Paid-up share capital in the September 30 balance sheet was Rs 69.8685 crore, compared with Rs 65.4515 crore at March 31, 2026.

Investments in subsidiaries used Rs 26.6861 crore in the half-year investing cash flow. Standalone investments on the balance sheet increased to Rs 356.0461 crore at September 30 from Rs 303.5497 crore at March 31, while total assets rose to Rs 524.6269 crore from Rs 388.6514 crore. Other current assets increased to Rs 34.1650 crore from Rs 5.1813 crore over the same period.

The September 2026 standalone results received a limited review from Bilimoria Mehta & Co., dated November 14, 2026. The reviewer stated that nothing had come to its attention indicating a material misstatement or inadequate required disclosure, while also stating that a review is substantially less extensive than an audit and does not provide an audit opinion.

Conclusion

Fischer Medical Ventures’ Rs 20.58 crore standalone September-quarter profit was associated with Rs 30.38 crore of other income, while operating revenue was Rs 27.62 lakh and expenses were Rs 4.58 crore. The half-year cash-flow statement identifies Rs 27.05 crore of dividend income in the operating reconciliation and reports Rs 33.45 crore of cash used in operating activities.

The next financial results will show whether revenue from operations recovers from Rs 99.79 lakh in the half year ended September 30, 2026 and whether other income continues to determine the standalone result. Investors can also monitor the deployment of Rs 77.5184 crore raised through warrant conversions, the Rs 26.6861 crore invested in subsidiaries, and cash receipts associated with recognised dividend income.